Status:

COMPLETED

Microarchitecture, Bone Strength and Fracture Risk in Long-term Type 1 Diabetes

Lead Sponsor:

Christian Meier

Collaborating Sponsors:

Insel Gruppe AG, University Hospital Bern

University Hospital Schleswig-Holstein

Conditions:

Type 1 Diabetes Mellitus

Eligibility:

All Genders

40-80 years

Phase:

NA

Brief Summary

This single center case control study will assess differences in bone structure between women and men with longstanding type 1 diabetes (diabetes duration\>/= 25 years) and healthy controls.

Detailed Description

Based on a cross-sectional approach the investigators aim to assess microstructural, biomechanical and densitometric bone characteristics in patients with longstanding type 1 diabetes and age- and sex...

Eligibility Criteria

Inclusion

  • women and men with longstanding type 1 diabetes (age 40-80 years, BMI 18-37 kg/m2 and age- and sex matched non-diabetic controls
  • presence of type 1 diabetes for at least 25 years (defined by history of Insulin treatment)

Exclusion

  • Patients unable to give written informed consent, e.g. with severe dementia or patients not understanding German (or other local language)
  • Any medical or psychiatric condition which would preclude the participant from adhering to the protocol
  • Idiopathic or premenopausal osteoporosis or coexisting metabolic bone disease (e.g. Paget´s disease, primary hyperparathyroidism)
  • Previous treatment with osteoporosis medication (bisphosphonates, denosumab) or intake of medications that are known to affect bone metabolism (e.g. steroids, anticonvulsants) within 6 months prior to enrollment
  • Patients with medical conditions known to affect bone health ( e.g. metastatic bone disease, celiac disease, inflammatory bone disease, hypogonadism, thyrotoxicosis, hypercortisolism, chronic kidney disease stage IV and V (KDIGO), liver dysfunction (serum aspartate amino transferase (ASAT) \>3 times the upper limit of normal)
  • Inability to keep the extremities still for a few minutes of an HR-pQCT examination (e.g. Parkinson disease, spastic syndrome)
  • Pregnant or breastfeeding women

Key Trial Info

Start Date :

October 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2021

Estimated Enrollment :

136 Patients enrolled

Trial Details

Trial ID

NCT03751839

Start Date

October 1 2018

End Date

July 1 2021

Last Update

July 27 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel

Basel, Canton of Basel-City, Switzerland, 4031